| Literature DB >> 34360133 |
Valérie Godefroy1, Richard Levy1,2,3, Arabella Bouzigues1, Armelle Rametti-Lacroux1, Raffaella Migliaccio1,2, Bénédicte Batrancourt1.
Abstract
Apathy, a common neuropsychiatric symptom associated with dementia, has a strong impact on patients' and caregivers' quality of life. However, it is still poorly understood and hard to define. The main objective of the ECOCAPTURE programme is to define a behavioural signature of apathy using an ecological approach. Within this program, ECOCAPTURE@HOME is an observational study which aims to validate a method based on new technologies for the remote monitoring of apathy in real life. For this study, we plan to recruit 60 couples: 20 patient-caregiver dyads in which patients suffer from behavioral variant Fronto-Temporal Dementia, 20 patient-caregiver dyads in which patients suffer from Alzheimer Disease and 20 healthy control couples. These dyads will be followed for 28 consecutive days via multi-sensor bracelets collecting passive data (acceleration, electrodermal activity, blood volume pulse). Active data will also be collected by questionnaires on a smartphone application. Using a pool of metrics extracted from these passive and active data, we will validate a measurement model for three behavioural markers of apathy (i.e., daytime activity, quality of sleep, and emotional arousal). The final purpose is to facilitate the follow-up and precise diagnosis of apathy, towards a personalised treatment of this condition within everyday life.Entities:
Keywords: Alzheimer disease; acceleration; apathy; blood volume pulse; electrodermal activity; fronto-temporal dementia; patient-caregiver dyads; remote monitoring; sensors
Mesh:
Year: 2021 PMID: 34360133 PMCID: PMC8345445 DOI: 10.3390/ijerph18157824
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Methodological characteristics and applications of ECOCAPTURE studies. AD: Alzheimer’s disease; FTD: frontotemporal dementia (behavioural variant); PD: Parkinson’s disease; EDA: electrodermal activity; HR: heart rate.
Figure 2Experimental design with two broad kinds of variables: (1) the behavioural markers of apathy (in green); (2) the caregiver’s perception of patient-caregiver status (in blue). EDA: electrodermal activity (or skin conductance); HR: heart rate.
Detailed description of visit 1.
| Inclusion (35 min) | |
|---|---|
| 5 min | After giving further information to the recruited couple on the objectives/conditions of the protocol and making sure that all is clearly understood, the investigator gives to both partners an information notice and collects their non-opposition to participate in the study. If a patient has a legal guardian, non-opposition is provided by the guardian and if a patient is under curatorship, non-opposition is provided by the patient with the help of their curator. |
| 5 min | For all the participants, the collection of demographics (age, sex, and education level), medical history (in particular, date of first symptoms and diagnosis for patients) and treatments. |
| 25 min | Verification of inclusion criteria including two tests: For patients, MMSE: general cognitive efficiency For all the participants, MADRS: depression symptoms. |
|
| |
| 30 min | For patients, |
| 30 min | For all the participants, Apathy Scale (AS, self-reported version) Dimensional Apathy Scale (DAS) Epworth Sleepiness Scale (ESS). |
|
| |
| 15 min |
Handing over two bracelets per couple; installation and configuration of a smartphone application for each partner for remote data collection; Training for the use of bracelets and application; for control dyads, random selection of the partner who fills the questionnaire (for active behavioural data) once a week; answering potential questions; Choice of a date for the first telephone conversation with the investigator during the 4-week remote follow-up. |
Figure 3Example of follow-up calendar for a patient-caregiver dyad. Sensors are worn by both patient and caregiver. Questionnaires are completed exclusively by the caregiver.
Figure 4Summarised data flow during the 28-day follow-up.